, Tracking Stock Market Picks
Enter Symbol:
Vical Incorporated (VICL) [hlAlert]

down 79.71 %

Vical Incorporated (VICL) rated Overweight with price target $5 by Thomas Weisel

Posted on: Friday,  Jun 12, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Vical Incorporated (NASDAQ: VICL) on 06/12/2009, when the stock price was $2.76. Since
then, Vical Incorporated has lost 79.71% as of 01/07/2016's recent price of $0.56.
If you would have followed this Thomas Weisel's recommendation on VICL, you would have lost 79.71% of your investment in 2400 days.

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/12/2009 8:25 AM Buy
2.76 5.00
as of 12/31/2009
1 Week down  -26.90 %
1 Month down  -29.72 %
3 Months down  -52.81 %
1 YTD down  -27.17 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy